Je dividenda Sysmex bezpečná?
Sysmex zvyšuje dividendu už 3 rokov.
V priebehu posledných 10 rokov Sysmex ročne -1,133 % znížené.
Na 5-ročnú perspektívu klesol výplata o -16,629 %.
Analytici očakávajú pre bežný obchodný rok nárast o Zníženie dividendy vo výške -0,657%.
Sysmex Aktienanalyse
Čo robí Sysmex?
Sysmex Corp is a Japanese company that has been a leading provider of diagnostic and analytical laboratory systems and solutions for the healthcare industry since its founding in 1968. The company is headquartered in Kobe, Japan and employs over 9,000 people worldwide.
History: Sysmex was founded by a group of young scientists in Japan who wanted to develop an automated blood cell analysis system to improve the high workload of manual blood analysis at the time. The company began developing this system and brought it to market in 1972.
Business model: Sysmex focuses on the development, production, and sale of diagnostic systems and solutions for medical laboratories around the world. The company specializes in hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology.
Divisions: Sysmex Corp is divided into three main business divisions:
1. Diagnostic Systems: This division includes hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology systems. Sysmex is one of the world's leading providers of hematology analysis devices and also offers molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer.
2. Information Solutions: This division offers software and IT solutions that support laboratory management and the integration of laboratory data to optimize analysis processes. The company also offers solutions for automating laboratory processes and managing laboratory inventory.
3. Life Science: This division focuses on the development of products for the life sciences, particularly cell analysis and imaging, as well as production, processing, and storage of cell cultures. Sysmex is also involved in the production of devices for harvesting mesenchymal stem cells from adipose tissue.
Products: Sysmex offers a variety of products, including:
- Hematology analysis devices for determining blood cell parameters such as RBC, WBC, HGB, HCT, and platelets.
- Hemostasis systems for analyzing blood coagulation.
- Molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer.
- Urinalysis systems for analyzing urine samples for chemical and microscopic parameters.
- Immunology analysis devices for determining specific proteins and antibodies in the blood.
- Clinical chemistry analysis devices for analyzing chemical parameters in blood samples.
- Software and IT solutions for optimizing laboratory processes and management.
- Cell analysis and imaging systems for investigating cell morphology and functions.
- Devices for harvesting mesenchymal stem cells from adipose tissue.
In summary, Sysmex Corp is a global leader in diagnostic and analytical laboratory systems and solutions for the healthcare industry. In its nearly 50-year history, the company has developed and produced a wide range of products that enable laboratories to perform fast and accurate disease diagnosis. The company has also expanded its business into other areas such as information solutions and the life sciences. Sysmex je jednou z najobľúbenejších spoločností na Eulerpool.com.Investičné plány do akcií ponúkajú atraktívnu možnosť pre investorov na dlhodobú výstavbu majetku. Jednou z hlavných výhod je tzv. Cost-Average-Effekt: Pravidelnou investíciou pevnej sumy do akcií alebo do akciových fondov automaticky kupujete viac podielov, keď sú ceny nízke, a menej, keď sú vysoké. To môže viesť k výhodnejšej priemernej cene za podiel v priebehu času. Okrem toho investičné plány do akcií umožňujú aj malým investorom prístup k drahým akciám, keďže sa dá investovať už s malými sumami. Pravidelná investícia tiež podporuje disciplinovanú investičnú stratégiu a pomáha predchádzať emocionálnym rozhodnutiam, ako je impulzívne kupovanie alebo predávanie. Ďalej investorom prináša potenciálny nárast hodnoty akcií, ako aj výplaty dividend, ktoré môžu byť reinvestované, čo zvyšuje efekt zloženého úroku a tým rast investovaného kapitálu.